DHODH inhibitors lead to ATP depletion with maintained ROS level, S phase arrest and upregulate the expression of p53, p65, and STAT6 proteins in sensitive T-47D and MDA-MB-231 breast cancer cells, compared with non-sensitive MDA-MB-436 and W3.006 breast cancer cells [56]. The gene discussed is TP53; the disease is breast carcinoma.